Cables

Vacuna de Moderna contra covid-19 genera al menos tres meses de inmunidad, señala estudio

Resultados de prueba realizada desde el inicio de los ensayos clínicos a 34 participantes

(FILES) In this file photo taken on November 18, 2020 shows a syringe and a bottle reading "Vaccine Covid-19" next to the Moderna biotech company logo. - US firm Moderna said it would file requests for emergency authorization of its Covid-19 vaccine in the United States and Europe on November 30, 2020, after full results confirmed a high efficacy estimated at 94.1 percent. "We believe that our vaccine will provide a new and powerful tool that may change the course of this pandemic and help prevent severe disease, hospitalizations and death," said the company's CEO Stephane Bancel. (Photo by JOEL SAGET / AFP) / -- IMAGE RESTRICTED TO EDITORIAL USE - STRICTLY NO COMMERCIAL USE --
(FILES) In this file photo taken on November 18, 2020 shows a syringe and a bottle reading "Vaccine Covid-19" next to the Moderna biotech company logo. - US firm Moderna said it would file requests for emergency authorization of its Covid-19 vaccine in the United States and Europe on November 30, 2020, after full results confirmed a high efficacy estimated at 94.1 percent. "We believe that our vaccine will provide a new and powerful tool that may change the course of this pandemic and help prevent severe disease, hospitalizations and death," said the company's CEO Stephane Bancel. (Photo by JOEL SAGET / AFP) / -- IMAGE RESTRICTED TO EDITORIAL USE - STRICTLY NO COMMERCIAL USE -- JOEL SAGET
‌
‌

‌

‌
‌

‌

‌